Search - tctmd.com

Displaying 381 - 400 of 1378

Sort: Relevancy | Date

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

Presentation Fellows 2017

The Evolution of Drug-Eluting Stents

Presenter: Ajay J. Kirtane

April 07, 2017

News Industry News

REVA Receives CE Mark for Fantom

April 04, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

Advertisement

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

The Evolution of Drug-Eluting Stents

REVA Receives CE Mark for Fantom

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Live From Washington: ACC 2017, Day One

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content